OpGen Inc (NASDAQ:OPGN) shares shot up 17.2% on Monday . The company traded as high as $2.32 and last traded at $2.25. 660,026 shares were traded during mid-day trading, an increase of 34% from the average session volume of 493,561 shares. The stock had previously closed at $1.92.
A number of brokerages have weighed in on OPGN. Zacks Investment Research downgraded shares of OpGen from a “buy” rating to a “hold” rating in a research report on Friday, February 16th. HC Wainwright upped their price objective on shares of OpGen to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Finally, ValuEngine upgraded shares of OpGen from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
The company has a debt-to-equity ratio of 0.03, a current ratio of 1.23 and a quick ratio of 1.13.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.